HOOKIPA Pharma Inc
HOOK0.900USD
+0.015+1.64%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
10.86MCap. mercado
PérdidaP/E TTM
Más Datos de HOOKIPA Pharma Inc Compañía
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Información de la empresa
Símbolo de cotizaciónHOOK
Nombre de la empresaHOOKIPA Pharma Inc
Fecha de salida a bolsaApr 18, 2019
Director ejecutivoDr. Malte Peters, M.D.
Número de empleados82
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 18
Dirección350 Fifth Avenue, 72Nd Floor, Suite 7240
CiudadNEW YORK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal10118
Teléfono114318906360
Sitio Webhttps://www.hookipapharma.com/
Símbolo de cotizaciónHOOK
Fecha de salida a bolsaApr 18, 2019
Director ejecutivoDr. Malte Peters, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
496.00
-0.20%
Mr. Sean A. Cassidy
Mr. Sean A. Cassidy
Independent Director
Independent Director
--
--
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Dr. David R. Kaufman, M.D., Ph.D.
Dr. David R. Kaufman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Terry Coelho
Ms. Terry Coelho
Chief Financial Officer, Executive Vice President, Director
Chief Financial Officer, Executive Vice President, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
496.00
-0.20%
Mr. Sean A. Cassidy
Mr. Sean A. Cassidy
Independent Director
Independent Director
--
--
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Dr. David R. Kaufman, M.D., Ph.D.
Dr. David R. Kaufman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Terry Coelho
Ms. Terry Coelho
Chief Financial Officer, Executive Vice President, Director
Chief Financial Officer, Executive Vice President, Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 15 de jun
Actualizado: dom., 15 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Gilead Sciences Inc
19.14%
Baker Bros. Advisors LP
8.29%
Invus Public Equities Advisors, LLC
5.78%
Knoll Capital Management, LLC
5.09%
Fidelity Management & Research Company LLC
3.43%
Other
58.26%
Accionistas
Accionistas
Proporción
Gilead Sciences Inc
19.14%
Baker Bros. Advisors LP
8.29%
Invus Public Equities Advisors, LLC
5.78%
Knoll Capital Management, LLC
5.09%
Fidelity Management & Research Company LLC
3.43%
Other
58.26%
Tipos de accionistas
Accionistas
Proporción
Corporation
19.16%
Hedge Fund
14.51%
Investment Advisor
13.49%
Venture Capital
3.38%
Investment Advisor/Hedge Fund
2.53%
Research Firm
0.25%
Individual Investor
0.13%
Other
46.54%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
100
5.23M
53.40%
-1.44M
2025Q1
107
5.24M
53.53%
-1.53M
2024Q4
113
5.54M
57.39%
-1.29M
2024Q3
117
5.65M
62.13%
+370.86K
2024Q2
126
5.73M
65.67%
+16.62K
2024Q1
159
5.79M
66.36%
+211.50K
2023Q4
171
5.72M
72.26%
+846.00
2023Q3
186
4.97M
68.46%
-1.10M
2023Q2
191
5.35M
75.93%
+1.70M
2023Q1
193
3.07M
61.74%
-790.10K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Gilead Sciences Inc
1.88M
19.16%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
812.81K
8.3%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
566.64K
5.79%
--
--
Mar 31, 2025
Knoll Capital Management, LLC
498.63K
5.09%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
336.46K
3.44%
-3.66K
-1.08%
Mar 31, 2025
Sofinnova Partners
314.26K
3.21%
+314.26K
--
Feb 14, 2025
The Vanguard Group, Inc.
300.82K
3.07%
+87.60K
+41.08%
Mar 31, 2025
Geode Capital Management, L.L.C.
73.43K
0.75%
+835.00
+1.15%
Mar 31, 2025
Acadian Asset Management LLC
55.73K
0.57%
-4.92K
-8.12%
Mar 31, 2025
Ikarian Capital LLC
53.00K
0.54%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
Fecha
Tipo
Relación
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
Jul 08, 2024
Merger
10<1
